COVID-19
IFPMA members commit to accelerate their effort to use their skills, technology and resources to bring safe, effective diagnostics, treatments and vaccines to patients around the world. Visit IFPMA COVID-19 Hub.
Read More
PHARMA CEO/TOP EXECUTIVES GLOBAL RESPONSE TO COVID-19 - VIRTUAL PRESS BRIEFING
On 30 April 2020, the global biopharmaceutical industry, represented by high-level executives/ CEO’s, took part in a virtual media briefing on the status of COVID-19 treatments
Watch more
Pharma CEO/Top Executives Global Response to COVID-19 - Virtual Press Briefing
On 19 March 2020, the global biopharmaceutical industry, represented by high-level executives/ CEO’s, took part in a virtual media briefing highlighting industry’s efforts and future commitments to address the current global coronavirus (COVID-19) crisis.
Watch More
Meet #GenerationGavi
Over the past 20 years, IFPMA and its members have proudly worked with Gavi, The Vaccine Alliance, to protect the most valuable resource on earth thanks to life saving vaccines: its children.
Read More
Health for All – Our Collaborations Supporting the SDGs
Our innovative partnerships are continually learning from each other, and through our deep and trusted collaborations we share insights and best practices from our experiences. Check out our NEW Global Health Progress Infographic.
Read More
IFPMA Note for Guidance on Patient and Patient Organization Interactions
Patient groups and pharma industry collaborate on a new guidance note on best practices for interaction
Read more
Global Health Progress - Collaborating for a sustainable future
Global Health Progress is an interactive knowledge hub highlighting over 200 collaborations between the innovative biopharmaceutical industry &; more than 850 diverse partners to support the SDGs & drive cross-sector collaboration. Explore our collaborations & learn more
Explore
New IFPMA Code of Practice 2019
New IFPMA Code of Practice will enter into force on 1st January 2019
New CodeIFPMA in Brief
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Tackling Global health challenges
The research-based biopharmaceutical industry is proud to be playing its part in the quest to find effective and sustainable solutions to today’s most pressing health concerns.
Read More
Boosting Innovation and Access
The research-based biopharmaceutical industry is thinking creatively about its innovation and business models to meet new challenges, and is working in collaboration with different players from the scientific community.
Read More
Strengthening Regulatory Systems
Patients everywhere should be treated with high quality medicines and vaccines. Science-based guidelines provide direction for the development, manufacture, and supply of medicines.
Read More
Building trust
The healthcare community and the public must be confident that research-based biopharmaceutical industry and their employees, wherever they operate, communicate and act in an ethical and professional manner.
Read More
Discovering medicines and Vaccines
Never have people lived longer and never have so many children been saved from dying in the first years of life. Medicines and vaccines extend and improve the quality of life for many people.
Read More
Our Resources
Global Health Progress – Collaborating for a sustainable future
Global Health Progress is a new knowledge hub highlighting over 200 collaborations between the innovative biopharmaceutical industry and more than 850 partners to support the SDGs. Users can explore collaborations by SDG target, disease area, program strategy, and more. Users are also encouraged to connect with partners via the platform...
Read More
Health for All in Africa - Our collaborations supporting the SDGs
Read More
Pharma CEO/Top Executives Global Response to COVID-19 - Virtual Press Briefing - 19 March 2020 (Video)
Read More
Global Biopharmaceutical Industry pulling out all the stops to address Coronavirus public health crisis
19 March 2020, Geneva – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), representing the world’s leading biopharmaceutical companies, today confirmed that having already mobilized on an unprecedented scale to respond to the COVID-19 pandemic, they commit to do more. The biopharmaceutical industry commits to accelerate its effort to...
Read More
Greg Perry - IFPMA Moderated Panels @Pre-ICDRA 2018
Read More
IFPMA Statement on the launch of a new global collaboration to accelerate the development, production and equitable access to new COVID-19 tools
Geneva, 24 April 2020 Statement delivered by: Thomas Cueni, Director General, IFPMA The biopharmaceutical industry is acutely aware of the enormous responsibility we have to patients and society to engage in unprecedented levels of collaboration to find a solution to COVID-19. We stand ready to bring to this partnership our...
Read More
Join IFPMA
Our membership has three levels tailored to meet specific needs. Full Members have to be R&D-based pharmaceutical companies or national associations whose membership includes innovative pharmaceutical companies; Associate Members of R&D-based pharmaceutical companies and national associations whose permanent staff numbers are less than five, and Affiliate Members that are organizations, associations, companies and institutions who are supportive of the R&D-based
LEARN MOREOur Blog
Intellectual property is not a hindrance but a help to end Covid-19
This was originally published in the Financial Times on Sunday, May 17, 2020. We must not send the wrong message to pharma companies that have taken huge risks As we confront an unprecedented public health, social and economic crisis brought about by Covid-19, our hopes are pinned on scientific innovation and, in particular, potential treatments and vaccines. While we have good reason to hope science...
Read More
Interview - CNN - What might happen when a Covid-19 vaccine is ready?
Thomas Cueni, IFPMA Director-General, spoke to CNN about the challenges to be faced in the manufacturing of a COVID-19 vaccine on a large-scale and how the industry, as a whole, will respond to the challenges. Click below to watch the full interview.
Read More
Speeding up the search for safe and effective COVID-19 therapies & vaccines – joining forces for a challenging road ahead
Last week, high-level representatives from seven companies – Takeda, Merck, AstraZeneca, CSL Behring, MSD, Pfizer and Sandoz – took part in a second IFPMA COVID-19 virtual media briefing dedicated to the on-going R&D efforts to find a treatment for COVID-19. It was an important milestone, taking stock of all that has been achieved in little more than the three months since the COVID-19 outbreak started...
Read MoreLatest Tweets
